Ocuphire Pharma, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Medical Advisory Board
  • Product Pipeline
    • Overview
    • Nyxol
    • APX3330
    • APX2009
    • Posters and Publications
  • Clinical Trials
    • Overview
    • VEGA-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia Enrolling
    • ZETA-1: Diabetic Retinopathy Phase 2 Clinical Trial for APX3330 Last Patient Last Visit Completed
    • MIRA-4: Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects Completed
    • MIRA-3 Completed
    • MIRA-2: Reversal of Mydriasis Phase 3 Clinical Trial for Nyxol Completed
    • LYNX-1: Dim Light Vision Disturbance Phase 3 Clinical Trial for Nyxol Completed
    • VEGA-1: Presbyopia Phase 2 Clinical Trial for Nyxol with Low-Dose Pilocarpine Completed
  • Partnerships
  • News & Media
    • Press Releases
    • Presentations
    • Events
    • Ocuphire in the News
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact
  • Careers

Ocuphire Pharma Enters into a Global License Agreement for Development and Commercialization of Nyxol Eye Drops for Reversal of Mydriasis, Presbyopia and Night Vision Disturbances

For more details, click here for the full news release.

Continue

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events
  • Ocuphire in the News

Rexahn Pharmaceuticals Receives Notice of Allowance for A New U.S. Patent Covering the Use of RX-5902 (Supinoxin™)

Jan 29, 2018

Rexahn Pharmaceuticals Announces Poster Presentation of RX-3117 Data in Metastatic Pancreatic Patients at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) 2018 Annual Meeting

Jan 22, 2018

Rexahn Pharmaceuticals to Present at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) 2018 Annual Meeting

Jan 18, 2018

Rexahn Pharmaceuticals to Present at Biotech Showcase™ 2018

Jan 8, 2018

Rexahn Pharmaceuticals Announces the Appointment of Douglas J. Swirsky as President and Chief Financial Officer

Jan 4, 2018

Rexahn Pharmaceuticals Presents New Preclinical Data on Supinoxin™ at the 2017 San Antonio Breast Cancer Symposium

Dec 11, 2017

Rexahn Pharmaceuticals to Present at the Stifel 2017 Healthcare Conference

Nov 9, 2017

Rexahn Pharmaceuticals Doses First Patient in a Phase IIa Clinical Trial of RX-3117 in Combination with Abraxane® in Patients Newly Diagnosed with Metastatic Pancreatic Cancer

Nov 8, 2017

Rexahn Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update

Nov 6, 2017

Rexahn Announces $8 Million Registered Direct Offering

Oct 13, 2017
    • 1...
    • 9
    • 10
    • 11
    • 12
    • 13
    • 14
    • 15
    • 16
    • 17
    • 18
    • ...40
    Ocuphire Pharma, Inc.
    © Ocuphire Pharma, Inc. All rights reserved. Privacy Policy Disclaimer Sitemap Terms of Use